FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial

BACKGROUND: Vascular leakage is a major feature of acute respiratory distress syndrome (ARDS). We aimed to evaluate the efficacy of FX06, a drug under development that stabilizes interendothelial cell junctions, at reducing vascular leakage during SARS-CoV-2-induced ARDS. METHODS: This multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Guérin, Emmanuelle, Belin, Lisa, Franchineau, Guillaume, Le Guennec, Loïc, Hajage, David, Diallo, Mamadou Hassimiou, Frapard, Thomas, Le Fèvre, Lucie, Luyt, Charles-Edouard, Combes, Alain, Germain, Stéphane, Hayon, Jan, Asfar, Pierre, Bréchot, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463389/
https://www.ncbi.nlm.nih.gov/pubmed/37641136
http://dx.doi.org/10.1186/s13054-023-04616-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463389/
https://www.ncbi.nlm.nih.gov/pubmed/37641136
http://dx.doi.org/10.1186/s13054-023-04616-1

Ejemplares similares